1 Haber, D. A. & Velculescu, V. E. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov4, 650-661, doi:10.1158/2159-8290.CD-13-1014 (2014).
2 Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med6, 224ra224, doi:10.1126/scitranslmed.3007094 (2014).
3 Rothwell, D. G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med25, 738-743, doi:10.1038/s41591-019-0380-z (2019).
4 Corcoran, R. B. & Chabner, B. A. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med379, 1754-1765, doi:10.1056/NEJMra1706174 (2018).
5 Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet20, 71-88, doi:10.1038/s41576-018-0071-5 (2019).
6 Diaz, L. A., Jr. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol32, 579-586, doi:10.1200/JCO.2012.45.2011 (2014).
7 Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med25, 1415-1421, doi:10.1038/s41591-019-0561-9 (2019).
8 Russo, M. et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov6, 147-153, doi:10.1158/2159-8290.CD-15-1283 (2016).
9 Merker, J. D. et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol36, 1631-1641, doi:10.1200/JCO.2017.76.8671 (2018).
10 Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A108, 9530-9535, doi:10.1073/pnas.1105422108 (2011).
11 Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol34, 547-555, doi:10.1038/nbt.3520 (2016).
12 Kang, J. K. et al. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. PLoS One15, e0232754, doi:10.1371/journal.pone.0232754 (2020).
13 Benson, A. B., 3rd et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw15, 370-398, doi:10.6004/jnccn.2017.0036 (2017).
14 Benson, A. B. et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw16, 874-901, doi:10.6004/jnccn.2018.0061 (2018).
15 Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer45, 228-247, doi:10.1016/j.ejca.2008.10.026 (2009).
16 Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res22, 568-576, doi:10.1101/gr.129684.111 (2012).
17 Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin)6, 80-92, doi:10.4161/fly.19695 (2012).
18 Robinson, J. T., Thorvaldsdottir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant Review with the Integrative Genomics Viewer. Cancer Res77, e31-e34, doi:10.1158/0008-5472.CAN-17-0337 (2017).
19 Bujang, M. A. & Adnan, T. H. Requirements for Minimum Sample Size for Sensitivity and Specificity Analysis. J Clin Diagn Res10, YE01-YE06, doi:10.7860/JCDR/2016/18129.8744 (2016).
20 Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res42, D980-985, doi:10.1093/nar/gkt1113 (2014).
21 Dasari, A. et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol17, 757-770, doi:10.1038/s41571-020-0392-0 (2020).
22 Keller, L., Belloum, Y., Wikman, H. & Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer124, 345-358, doi:10.1038/s41416-020-01047-5 (2021).
23 Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer1, 276-290, doi:10.1038/s43018-020-0043-5 (2020).
24 Strickler, J. H. et al. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov8, 164-173, doi:10.1158/2159-8290.CD-17-1009 (2018).
25 Schrock, A. B. et al. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res24, 1881-1890, doi:10.1158/1078-0432.CCR-17-3103 (2018).
26 Thierry, A. R. et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med20, 430-435, doi:10.1038/nm.3511 (2014).
27 Vidal, J. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol28, 1325-1332, doi:10.1093/annonc/mdx125 (2017).
28 Grasselli, J. et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol28, 1294-1301, doi:10.1093/annonc/mdx112 (2017).
29 Hsu, H. C. et al. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer. Mol Cancer Ther17, 2238-2247, doi:10.1158/1535-7163.MCT-17-1306 (2018).
30 Normanno, N. et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol29, 112-118, doi:10.1093/annonc/mdx417 (2018).
31 Ducreux, M. et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol11, 1758835919856494, doi:10.1177/1758835919856494 (2019).
32 Baldus, S. E. et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res16, 790-799, doi:10.1158/1078-0432.CCR-09-2446 (2010).
33 Mao, C. et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep5, 8065, doi:10.1038/srep08065 (2015).
34 Hrebien, S. et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol30, 945-952, doi:10.1093/annonc/mdz085 (2019).
35 Tie, J. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol26, 1715-1722, doi:10.1093/annonc/mdv177 (2015).
36 Frenel, J. S. et al. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res21, 4586-4596, doi:10.1158/1078-0432.CCR-15-0584 (2015).
37 Davis, A. A. et al. Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Mol Cancer Ther19, 1486-1496, doi:10.1158/1535-7163.MCT-19-1060 (2020).